COPS5, which is overexpressed in HCC in an amplification‐ and ATF4‐dependent manner, stabilizes MK2 through deubiquitination and, in turn, induces HSPB1 activation, protecting HCC cells from ferroptosis and thus promoting sorafenib resistance and tumor progression. The gene discussed is ATF4; the disease is neoplasm.